Full Description
Lipid disorders are among the primary risk factors in developing atherosclerosis and heart disease. Cardiovascular diseases are the leading cause of death world-wide in both genders. This book provides the inquiring physician with an up-to-date insight into the latest research into lipid disorders, and the implications of this research for daily clinical practice. The book provides an overview of the latest developments in this complex field by reviewing the most significant papers published in the medical journals on lipid disorders over the eighteen months to December 2006. "The Year in Lipid Disorders" will be an essential element of the reference library for all cardiovascular physicians.
Contents
Preface; PART I: Clinical aspects in coronary artery disease; 1. Metabolic syndrome, diabetes & CHD risk, C Byrne; 2. Use of novel risk factors in prevention and therapeutic strategies, N Sattar; 3. Diet & exercise in the prevention & treatment of CHD, J Tuomilehto; 4. Technologies for assessment of atherosclerotic burden in man, C Berry, J McMurray; PART II: Lipids, lipoproteins & atherosclerosis; 5. HDL structure & metabolism: its regulation by cell membrane receptors, K-A Rye; 6. Oxidative stress, LDL oxidation, and atherosclerosis, tbc; 7. Metabolism of apoB containing lipoproteins in dyslipidaemia, G Watts; 8. Sex specific aspects of dyslipidaemia and atherosclerosis; (dyslipidaemia in pre-eclampsia and in utero programming of CHD risk), tbc; PART III: Prevention and treatment strategies; 9. New clinical trials of lipid regulating agents, AG Olsson; 10. Genetics of dyslipidaemia & coronary risk; (personalised lipid lowering treatment), P Talmud; 11. The application of proteomic & lipidomic approaches to CHD risk prediction, F McTaggart; 12. New drug targets; nuclear receptors (PPARS, LXR, FXR) and their role in regulating lipid metabolism, A Catapano; PART IV: Infection, inflammation and secondary causes of atherosclerosis; 13. Inflammation, inflammatory disease, and atherosclerosis, R Rosensen; 14. Kidney disease, end stage renal failure & accelerated CHD, M Tonnelli; 15. Chronic infection(s) and lipids, M Bassendine; 16. Haemaeostasis, dyslipidemia interactions in CHD, GY Lip; List of abbreviations; Index of papers reviewed; General index.
